

This listing of claims will replace all prior versions, and listing, of claims in the application:

**In the Claims:**

Claims 1-22 (canceled)

Claim 23 (withdrawn): An isolated human endothelin receptor having an affinity for endothelins 1 and 2, comprising an amino acid sequence from Asp at 1 to Asn at 407 of SEQ ID NO: 1.

Claim 24 (withdrawn): An isolated human endothelin receptor precursor comprising an amino acid sequence from Met at -20 to Asn at 407 of SEQ ID NO: 1.

Claim 25 (withdrawn): A method for identifying an agonist or an antagonist of a human endothelin receptor, comprising the steps of:

contacting a sample comprising an endothelin receptor according to claim 23 with a candidate compound; and

detecting binding of the candidate compound to the endothelin receptor.

Claim 26 (withdrawn): The method of claim 25, wherein the sample comprises a cell expressing the receptor of claim 23.

Claim 27 (withdrawn): The method of claim 26, wherein the cell contains a DNA molecule comprising a nucleic acid sequence from G at 545 to C at 1765 shown in SEQ ID NO: 1.

Claim 28 (withdrawn): A method of manufacturing a pharmaceutical composition, comprising the steps of:

- screening a library of candidate compounds by:
- contacting a sample comprising an endothelin receptor according to claim 23 with each candidate compound in the library,
- detecting binding of the candidate compound to the endothelin receptor, and
- identifying compounds which bind to the endothelin receptor;
- selecting an target compound identified from the library; and
- formulating said target compound with a pharmaceutically acceptable carrier.

Claim 29 (withdrawn): The method of claim 28, wherein the sample comprises a cell expressing the receptor of claim 23.

Claim 30 (withdrawn): The method of claim 29, wherein the cell contains a DNA molecule comprising a nucleic acid sequence from G at 545 to C at 1765 shown in SEQ ID NO: 1.

Claim 31 (withdrawn): A pharmaceutical composition produced by the method of claim 28.

Claim 32 (withdrawn): A method of modulating an endothelin receptor, comprising the steps of:

- screening a library of candidate compounds by:
- contacting a sample comprising an endothelin receptor according to claim 23 with each candidate compound in the library,
- detecting binding of the candidate compound to the endothelin receptor, and
- identifying compounds which bind to the endothelin receptor;

selecting a target compound identified from the library; and  
contacting the endothelin receptor with the target compound.

Claim 33 (withdrawn): The method of claim 32, wherein the sample comprises a cell expressing the receptor of claim 23.

Claim 34 (withdrawn): The method of claim 33, wherein the cell contains a DNA molecule comprising a nucleic acid sequence from G at 545 to C at 1765 shown in SEQ ID NO: 1.

Claim 35 (currently amended): A method of treating ~~a condition characterized by abnormal activity of endothelin receptors~~ a circulatory system disease in a subject, comprising the steps of:

screening a library of candidate compounds by:

contacting a sample comprising a human endothelin receptor having an affinity for endothelins 1 and 2, comprising an amino acid sequence from Asp at 1 to Asn at 407 of SEQ ID NO: [[2]] 1 with each candidate compound in the library,

detecting binding of the candidate compound to the endothelin receptor, and

identifying compounds which bind to the endothelin receptor;

selecting a target compound identified from the library; and

administering the target compound to the subject.

Claim 36 (currently amended): The method of claim 35, wherein the sample comprises a cell expressing a human endothelin receptor having an affinity for endothelins 1 and 2, comprising an amino acid sequence from Asp at 1 to Asn at 407 of SEQ ID NO: [[2]] 1.

Claim 37 (previously presented): The method of claim 36, wherein the cell contains a DNA molecule comprising a nucleic acid sequence from G at 545 to C at 1765 shown in SEQ ID NO: 1.

Claim 38 (withdrawn): A method of determining ET-1 or ET-2 in a sample, comprising the steps of:

contacting the sample with an endothelin receptor according to claim 23,  
wherein the endothelin receptor is present on a cell membrane; and  
detecting binding of the sample to the endothelin receptor.

Claim 39 (withdrawn): The method of claim 38, wherein the cell contains a DNA molecule comprising a nucleic acid sequence from G at 545 to C at 1765 shown in SEQ ID NO: 1.